BioTuesdays

Category - Markets

CannTrust Holdings
Markets

Paradigm starts CannTrust Holdings at buy; PT $18

Paradigm Capital launched coverage of CannTrust Holdings (TSX:TRST) with a “buy” rating and $18 price target. The stock closed at $8.35 on Jan.18. “CannTrust brings to the cannabis space a practice of professionalism...

January 18, 2019
Markets

HCW ups Aeterna Zentaris PT to $5.50 from $3

H.C. Wainwright raised its price target for Aeterna Zentaris (NASDAQ, TSX:AEZS) to $5.50 from $3 after its Macrilen agent for adult growth hormone deficiency (AGHD) was approved for sale in the EU. The stock closed at...

January 17, 2019
Puma Biotechnology Logo
Markets

Leerink starts Puma Biotech at MP; PT $21

Leerink launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “market perform” rating and $21 price target. The stock closed at $25.33 on Jan. 16. Puma is a single-product commercial-stage biotech company...

January 17, 2019
Dyadic
Markets

Noble starts Dyadic at OP; PT $4

Noble Capital Markets initiated coverage of Dyadic International (OTC:DYAI) with an “outperform” rating and price target of $4. The stock closed at $1.96 on Jan. 9. Over the past two decades, Dyadic has developed an...

January 10, 2019
Canopy Growth Logo
Markets

Piper Jaffray starts Canopy Growth at OW; PT $40

Piper Jaffray launched coverage of Canopy Growth (NYSE:CGC; TSX:WEED) with an “overweight” rating and $40 price target. The stock was quoted at $32.16, up $2.52, around midday on Jan 9. “While it is difficult to...

January 9, 2019
Millendo Therapeutics
Markets

Ladenburg starts Millendo Therapeutics at buy; PT $29

Ladenburg Thalmann launched coverage of Millendo Therapeutics (NASDAQ:MLND) with a “buy” rating and $29 price target. The stock closed at $7.65 on Jan. 3. Millendo is a clinical-stage company focusing on the development...

January 4, 2019
Chembio Diagnostics
Markets

Canaccord starts Chembio Diagnostics at buy; PT $9

Canaccord Genuity launched coverage of Chembio Diagnostics (NASDAQ:CEMI) with a “buy” rating and $9 price target. The stock closed at $5.48 on Jan. 3. “In our opinion, Chembio is an underappreciated player in the...

January 4, 2019
Synthorx
Markets

HCW starts Synthorx at buy; PT $30

H.C. Wainwright initiated coverage of Synthorx (NASDAQ:THOR) with a “buy” rating and $30 price target. The stock closed at $17.38 on Dec. 31. Synthorx’s Expanded Genetic Alphabet (EGA) technology generates a modular...

January 2, 2019